RU2018142835A - Вариантные последовательности оболочки флавивируса и пути их применения - Google Patents
Вариантные последовательности оболочки флавивируса и пути их применения Download PDFInfo
- Publication number
- RU2018142835A RU2018142835A RU2018142835A RU2018142835A RU2018142835A RU 2018142835 A RU2018142835 A RU 2018142835A RU 2018142835 A RU2018142835 A RU 2018142835A RU 2018142835 A RU2018142835 A RU 2018142835A RU 2018142835 A RU2018142835 A RU 2018142835A
- Authority
- RU
- Russia
- Prior art keywords
- analogue
- paragraphs
- flavivirus
- protein
- composition
- Prior art date
Links
- 241000710831 Flavivirus Species 0.000 title claims 20
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 101710145006 Lysis protein Proteins 0.000 claims 8
- 241000725619 Dengue virus Species 0.000 claims 6
- 101710088839 Replication initiation protein Proteins 0.000 claims 6
- 241000907316 Zika virus Species 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 238000002405 diagnostic procedure Methods 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 108020004511 Recombinant DNA Proteins 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 150000004676 glycans Chemical class 0.000 claims 4
- 230000012743 protein tagging Effects 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 230000001900 immune effect Effects 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 206010054261 Flavivirus infection Diseases 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000001279 glycosylating effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1608896.5A GB2550418A (en) | 2016-05-20 | 2016-05-20 | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
| GB1608896.5 | 2016-05-20 | ||
| PCT/US2017/033882 WO2017201543A1 (en) | 2016-05-20 | 2017-05-22 | Variant flavivirus envelope sequences and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018142835A true RU2018142835A (ru) | 2020-06-22 |
Family
ID=56369688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142835A RU2018142835A (ru) | 2016-05-20 | 2017-05-22 | Вариантные последовательности оболочки флавивируса и пути их применения |
Country Status (18)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2550418A (en) * | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
| EP3474891B1 (en) * | 2016-06-23 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vaccine compositions comprising an attenuated mutant zika virus |
| WO2018208547A1 (en) | 2017-05-10 | 2018-11-15 | University Of Massachusetts | Bivalent dengue/hepatitis b vaccines |
| TWI658848B (zh) * | 2018-02-13 | 2019-05-11 | 國立清華大學 | 茲卡病毒疫苗組合物及其應用 |
| CN109627294B (zh) * | 2018-12-29 | 2020-10-09 | 四川大学 | 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用 |
| WO2020198865A1 (en) * | 2019-04-03 | 2020-10-08 | The University Of British Columbia | Oligopeptides for quantitative viral proteomic analysis methods and uses |
| CN114907457B (zh) * | 2019-11-07 | 2025-05-30 | 中国科学院微生物研究所 | 一种寨卡/登革疫苗及其应用 |
| JP2023546048A (ja) * | 2020-10-07 | 2023-11-01 | サノフィ・パスツール | 改良された診断試験 |
| GB202019843D0 (en) | 2020-12-16 | 2021-01-27 | Coronex Ltd | Lateral flow tests |
| WO2024081625A1 (en) * | 2022-10-11 | 2024-04-18 | University Of Maryland, Baltimore | Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| US8017754B2 (en) | 2005-07-22 | 2011-09-13 | Research Development Foundation | Attenuated virus strains and uses thereof |
| US7943148B1 (en) | 2007-04-04 | 2011-05-17 | The United States Of America As Represented By The Secretary Of The Army | Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines |
| CN108912215A (zh) * | 2012-04-02 | 2018-11-30 | 北卡罗来纳-查佩尔山大学 | 用于登革病毒表位的方法和组合物 |
| GB201413086D0 (en) * | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
| GB2550418A (en) * | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
-
2016
- 2016-05-20 GB GB1608896.5A patent/GB2550418A/en not_active Withdrawn
-
2017
- 2017-05-22 PE PE2018003079A patent/PE20190130A1/es unknown
- 2017-05-22 JP JP2018561062A patent/JP7121396B2/ja active Active
- 2017-05-22 SG SG11201810157QA patent/SG11201810157QA/en unknown
- 2017-05-22 MX MX2018014198A patent/MX2018014198A/es unknown
- 2017-05-22 WO PCT/US2017/033882 patent/WO2017201543A1/en not_active Ceased
- 2017-05-22 RU RU2018142835A patent/RU2018142835A/ru not_active Application Discontinuation
- 2017-05-22 CA CA3025076A patent/CA3025076A1/en active Pending
- 2017-05-22 HU HUE17726515A patent/HUE049543T2/hu unknown
- 2017-05-22 KR KR1020187036317A patent/KR20190008896A/ko not_active Abandoned
- 2017-05-22 DK DK17726515.4T patent/DK3458471T3/da active
- 2017-05-22 US US16/303,588 patent/US11028133B2/en not_active Expired - Fee Related
- 2017-05-22 AU AU2017268479A patent/AU2017268479B2/en not_active Ceased
- 2017-05-22 CN CN201780040802.7A patent/CN109415414A/zh active Pending
- 2017-05-22 EP EP17726515.4A patent/EP3458471B1/en not_active Not-in-force
- 2017-05-22 BR BR112018073681-3A patent/BR112018073681A2/pt not_active IP Right Cessation
- 2017-11-22 GB GBGB1719423.4A patent/GB201719423D0/en not_active Ceased
-
2018
- 2018-05-22 US US16/615,788 patent/US11401307B2/en active Active
- 2018-05-22 EP EP18725547.6A patent/EP3630796A1/en not_active Withdrawn
- 2018-05-22 WO PCT/EP2018/063422 patent/WO2018215495A1/en not_active Ceased
- 2018-11-15 IL IL263054A patent/IL263054A/en unknown
- 2018-11-20 PH PH12018502441A patent/PH12018502441A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3458471B1 (en) | 2020-03-25 |
| WO2017201543A1 (en) | 2017-11-23 |
| CA3025076A1 (en) | 2017-11-23 |
| PH12018502441A1 (en) | 2019-05-15 |
| MX2018014198A (es) | 2019-08-21 |
| SG11201810157QA (en) | 2018-12-28 |
| IL263054A (en) | 2019-01-31 |
| EP3630796A1 (en) | 2020-04-08 |
| US20200215180A1 (en) | 2020-07-09 |
| AU2017268479A1 (en) | 2018-12-06 |
| AU2017268479B2 (en) | 2021-04-01 |
| DK3458471T3 (da) | 2020-07-06 |
| EP3458471A1 (en) | 2019-03-27 |
| JP7121396B2 (ja) | 2022-08-18 |
| BR112018073681A2 (pt) | 2019-02-26 |
| GB2550418A (en) | 2017-11-22 |
| JP2019520058A (ja) | 2019-07-18 |
| US11401307B2 (en) | 2022-08-02 |
| WO2018215495A1 (en) | 2018-11-29 |
| KR20190008896A (ko) | 2019-01-25 |
| CN109415414A (zh) | 2019-03-01 |
| GB201608896D0 (en) | 2016-07-06 |
| US20190300580A1 (en) | 2019-10-03 |
| GB201719423D0 (en) | 2018-01-03 |
| HUE049543T2 (hu) | 2020-09-28 |
| US11028133B2 (en) | 2021-06-08 |
| PE20190130A1 (es) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018142835A (ru) | Вариантные последовательности оболочки флавивируса и пути их применения | |
| JP2019520058A5 (cg-RX-API-DMAC7.html) | ||
| Chávez et al. | Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization | |
| JP6018575B2 (ja) | デングウイルス組換えサブユニットスワクチン | |
| AU2007246076B2 (en) | Methods for the treatment of flavivirus infection, molecules and uses thereof | |
| Zu et al. | Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III | |
| Lazo et al. | A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus | |
| KR20090053930A (ko) | 재조합 ｈｃｖ ｅ2 당단백질 | |
| Chiu et al. | Blocking the dengue virus 2 infections on BHK-21 cells with purified recombinant dengue virus 2 E protein expressed in Escherichia coli | |
| Xie et al. | Generation and characterization of mouse monoclonal antibodies against NS4B protein of dengue virus | |
| Chen et al. | Comprehensive mapping of immunodominant and conserved serotype-and group-specific B-cell epitopes of nonstructural protein 1 from dengue virus type 1 | |
| Fan et al. | Inhibition of Japanese encephalitis virus infection by flavivirus recombinant E protein domain III | |
| US20040213808A1 (en) | Recombinant vaccine against flavivirus infection | |
| Zhou et al. | Identification of a protective epitope in Japanese encephalitis virus NS1 protein | |
| Ganguly et al. | Enhanced prokaryotic expression of dengue virus envelope protein | |
| Tong et al. | The epitope recognized by monoclonal antibody 2B6 in the B/C domains of classical swine fever virus glycoprotein E2 affects viral binding to hyperimmune sera and replication | |
| Li et al. | Cross protection against lethal West Nile virus challenge in mice immunized with recombinant E protein domain III of Japanese encephalitis virus | |
| ES2701033T3 (es) | Procedimiento para la detección y el serotipaje precoz del virus del dengue | |
| US20050287170A1 (en) | Subunit vaccine against West Nile viral infection | |
| Aghasadeghi et al. | Evaluation of a native preparation of HCV core protein (2-122) for potential applications in immunization, diagnosis and mAb production | |
| US20250002566A1 (en) | Polynucleotide, expression cassette, vector, host cell, polypeptide, pharmaceutical composition, use of a polypeptide, method for producing a polypeptide, and method for preventing or treating infections caused by flaviviruses | |
| Huang et al. | Identification of neutralizing epitopes on the D/A domain of the E2 glycoprotein of classical swine fever virus | |
| Mulyaningrum et al. | Immunogenicity and reactivity of recombinant Zika virus NS1 inclusion bodies from an Indonesian isolate | |
| Kuzmina et al. | Antigenicity and B-epitope mapping of hepatitis C virus envelope protein E2 | |
| WO2013021163A1 (en) | Peptide markers and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200525 |